Central Pharmaceutical JSC No2 (HSTC:DP2) Return-on-Tangible-Equity: 0.00% (As of . 20)


HSTC:DP2 Central Pharmaceutical JSC No2 HSTC:DP2
23 GF Score
Price ₫4,500.00
View Full Analysis

What is Central Pharmaceutical JSC No2 Return-on-Tangible-Equity?

Central Pharmaceutical JSC No2 HSTC:DP2 23 Return-on-Tangible-Equity is 0.00% as of . 20. GuruFocus rates HSTC:DP2 with a GF Score™ of 23/100.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Central Pharmaceutical JSC No2's annualized net income for the quarter that ended in . 20 was ₫ Mil. Central Pharmaceutical JSC No2's average shareholder tangible equity for the quarter that ended in . 20 was ₫ Mil. Therefore, Central Pharmaceutical JSC No2's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 was %.

The historical rank and industry rank for Central Pharmaceutical JSC No2's Return-on-Tangible-Equity or its related term are showing as below:

HSTC:DP2's Return-on-Tangible-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 10.065
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Central Pharmaceutical JSC No2  (HSTC:DP2) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Central Pharmaceutical JSC No2 Return-on-Tangible-Equity Related Terms


Central Pharmaceutical JSC No2 Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Central Pharmaceutical JSC No2's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Pharmaceutical JSC No2 Return-on-Tangible-Equity Chart

Central Pharmaceutical JSC No2 Annual Data
Trend
Return-on-Tangible-Equity

Central Pharmaceutical JSC No2 Semi-Annual Data
Return-on-Tangible-Equity

HSTC:DP2 vs : Return-on-Tangible-Equity Comparison

For the Pharmaceutical Retailers subindustry, Central Pharmaceutical JSC No2's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Central Pharmaceutical JSC No2 Return-on-Tangible-Equity vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Central Pharmaceutical JSC No2's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Central Pharmaceutical JSC No2's Return-on-Tangible-Equity falls into.


HSTC:DP2
23GF Score
Central Pharmaceutical JSC No2 HSTC:DP2
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Central Pharmaceutical JSC No2 Return-on-Tangible-Equity Calculation

Central Pharmaceutical JSC No2's annualized Return-on-Tangible-Equity for the fiscal year that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+ )/ )
=/
= %

Central Pharmaceutical JSC No2's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (. 20) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Central Pharmaceutical JSC No2 (HSTC:DP2) has a Return-on-Tangible-Equity of 0.00% as of . 20. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Central Pharmaceutical JSC No2 and its competitors.
Is Central Pharmaceutical JSC No2's Return-on-Tangible-Equity too high?
Central Pharmaceutical JSC No2's current Return-on-Tangible-Equity is 0.00%. Overall, Central Pharmaceutical JSC No2 has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceutical JSC No2's Return-on-Tangible-Equity compare to ?
Central Pharmaceutical JSC No2's Return-on-Tangible-Equity of 0.00% can be compared against companies in the Healthcare Providers & Services industry. The industry median Return-on-Tangible-Equity is 10.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.07, based on 582 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Central Pharmaceutical JSC No2 and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Central Pharmaceutical JSC No2's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceutical JSC No2 stock overvalued right now?
Central Pharmaceutical JSC No2 (HSTC:DP2) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Central Pharmaceutical JSC No2's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Central Pharmaceutical JSC No2 (HSTC:DP2), the current Return-on-Tangible-Equity is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Central Pharmaceutical JSC No2 Business Description

Comparable Companies
Address No. 9 Tran Thanh Tong, Bach Dang Ward, Hai Ba Trung District, Hanoi, VNM
Central Pharmaceutical JSC No2 is engaged in the Trading of medicinal materials, pharmaceutical materials, chemicals, essential oils, modern medicines, traditional medicine drugs, cosmetics, and nutritious foods. Some of its products include Gentamycin injection solution 80; Genatreson Skin Cream; Ferimax Hard Capsules and others.
23GF Score

Get the complete analysis for HSTC:DP2

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫4,500.00
Price